Cambrex and AstraZeneca Mark Long-Term Supply Agreement at Sweden Site

Cambrex, a manufacturer of small molecule innovator and generic APIs, held an opening ceremony on Jan.16, 2018 at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement with AstraZeneca for a key intermediate. The announcement follows the completion of both a large-scale, multi-purpose capacity expansion, which also includes hydrogenation capabilities, and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.  

Speaking at the ceremony, Juliette White, vice-president, Global External Sourcing, AstraZeneca, commented, “Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery.” She added, “We look forward to a successful collaboration with Cambrex.”

Shawn Cavanagh, COO of Cambrex, stated, “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products.” He added, “We will continue to invest in capabilities, technology, and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand.”

Cambrex’s Karlskoga, site develops and manufactures small molecule APIs, new chemical entities (NCEs), and intermediates from grams to tons, through all phases of the drug lifecycle. Featuring a range of flexible manufacturing facilities including kilo scale, pilot scale, and large-scale commercial production plants, the site houses a combination of GMP and non-GMP work, providing classic and advanced chemistry capabilities, continuous processes, and high-energy chemistry expertise.

Source: Cambrex